In view of this, the study conducted by Sorace et al. observed an improvement in vascularization and intratumoral delivery of drug therapies under trastuzumab treatment in a BT474 mouse model of HER2+ breast cancer [48]. The gene discussed is ERBB2; the disease is breast carcinoma.